Stress and the Nervous System
Status
Conditions
Treatments
Details and patient eligibility
About
Models of stress such as hypoglycemia have identified that stress results the next day in decreased baroreflex sensitivity. This project will test the hypothesis that these delayed changes in autonomic nervous system function are secondary to a rise in ACTH. The investigators will infuse cosyntropin versus placebo in a double-blind, crossover study in healthy adults and measure the delayed effects on the autonomic system as measured by cardiovagal baroreflex sensitivity.
Full description
Stress has complex effects on the body's physiology. Models of stress such as hypoglycemia have identified that stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathoadrenal system acutely. Additionally, there are delayed effects of prior exposure to hypoglycemia. The day after being exposed to a hypoglycemic stimulus there are: 1) decreases in the catecholamine release to a new hypoglycemic stress; 2) decreases in the muscle sympathetic nerve activity (MSNA) response to either a new hypoglycemic challenge or transient hypotension; 3) decreases in cardiac vagal baroreflex sensitivity (BRS); and 4) increases in sensitivity to thermal pain and altered temporal summation (decreased tolerance to a repeated minimally painful stimulus). This project will test the hypothesis that these delayed changes in autonomic nervous system function are secondary to a rise in ACTH that occurs in response to stress.
Primary Aim. Infusion of ACTH (cosyntropin) will lead the next day to decreased cardiovagal baroreflex sensitivity in healthy subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects must be currently healthy, BMI 18-32 kg/m2, and not be on any medications.
This study will recruit men and women. Due to concerns about estrogen's effects on hormone levels and possible contributions of menstrual symptoms on pain sensing thresholds, we will schedule the inpatient studies to avoid the early follicular phase in normally cycling women.
Subjects must have normal laboratory values for:
- Complete blood count
- Serum creatinine, sodium, potassium, glucose, liver enzymes
- Urinalysis
- Urine pregnancy test (if female)
- Normal ECG
Exclusion criteria
We will exclude individuals with:
- Systolic blood pressure > 140 or < 90 mm Hg
- Diastolic blood pressure > 90 mm Hg
- Creatinine clearance ≤ 60 mL/min, as calculated by MDRD formula
- Known DM, CHF, CAD, PVD, CVA, MI, asthma
- Known or history of Cushing's disease or adrenal insufficiency
- Known neurologic disease
- Known psychiatric disease
- Steroid use (oral or inhaled, local or systemic injections, within the past 6 months)
- Significant concomitant medical illnesses
- Current excessive alcohol (>10oz ethanol/week)
- Current use of recreational drugs
- Current smokers
- Current pregnancy
- Chronic use of non-steroidal anti-inflammatory or narcotic medications
- Evidence of ischemia or heart block on screening electrocardiogram (greater than type I-second degree heart block, left bundle branch block, or ST-T wave changes in 2 or more contiguous leads)
- Subjects taking any prescription medications (other than oral birth control pills) or herbal medications will be excluded.
Trial design
Primary purpose
Allocation
Interventional model
Masking
23 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal